Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study
Status:
Not yet recruiting
Trial end date:
2026-10-10
Target enrollment:
Participant gender:
Summary
Emergent reperfusion is the main goal for acute ischemic stroke therapy (AIS). Endovascular
therapy (EVT) is recommended within 6 hrs of stroke onset, and up to 24 hrs following
perfusion imaging criteria.
Despite the major benefit associated with MT, more than 50% of the patients remain disabled
at 3 months. Reperfusion rates after MT are critical to determine functional outcome.
However, complete reperfusion is obtained in only 50 % of the patients, due to, at least in
part, erratic emboli and/or no-reflow processes. The aim of this study is to evaluate the
efficacy of glenzocimab in addition to EVT and compared to EVT plus placebo, whether or not
associated with ntravenous thrombolysis (IVT), on functional outcome at day 90.